NASDAQ:VRCA - Verrica Pharmaceuticals Stock Price, Forecast & News

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) announced its earnings results on Wednesday, November, 6th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. View Verrica Pharmaceuticals' Earnings History.

Verrica Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Verrica Pharmaceuticals.

1 Wall Street analysts have issued 12-month target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $24.00 to $24.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price. View Analyst Price Targets for Verrica Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verrica Pharmaceuticals.

News headlines about VRCA stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Verrica Pharmaceuticals.

Verrica Pharmaceuticals saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 573,300 shares, a drop of 10.7% from the December 31st total of 641,900 shares. Based on an average daily trading volume, of 72,600 shares, the short-interest ratio is currently 7.9 days. Currently, 4.7% of the shares of the company are sold short. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include TG Therapeutics (TGTX), Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Zogenix (ZGNX), Akebia Therapeutics (AKBA) and Rocket Pharmaceuticals (RCKT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Aurora Cannabis (ACB), Exxon Mobil (XOM), Foamix Pharmaceuticals (FOMX), Global Blood Therapeutics (GBT), Progenics Pharmaceuticals (PGNX), Citigroup (C), Enterprise Products Partners (EPD) and Energy Transfer LP Unit (ET).

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Verrica Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.47%), Kornitzer Capital Management Inc. KS (1.72%), Fosun International Ltd (1.60%), State Street Corp (0.87%), Geode Capital Management LLC (0.63%) and Steel Peak Wealth Management LLC (0.51%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View Institutional Ownership Trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Kornitzer Capital Management Inc. KS, Bank of America Corp DE and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Verrica Pharmaceuticals.

VRCA stock was purchased by a variety of institutional investors in the last quarter, including Steel Peak Wealth Management LLC, Geode Capital Management LLC, State Street Corp, Renaissance Technologies LLC, California Public Employees Retirement System, Alliancebernstein L.P., FMR LLC and Goldman Sachs Group Inc.. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort and Ted White. View Insider Buying and Selling for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $12.85.

Verrica Pharmaceuticals has a market capitalization of $331.21 million. The company earns $-20,650,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.View Additional Information About Verrica Pharmaceuticals.

The official website for Verrica Pharmaceuticals is http://www.verrica.com/.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]